



Divi's Laboratories Limited

Date. 5th February 2016

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

Dear Sir,

**Sub: Un-audited financial results for the quarter and nine months ended
31st December 2015 and limited review report –reg**
Ref: Stock code: DIVISLAB

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed un-audited financial results along with the limited review report for the quarter and nine months ended 31st December 2015.

Above un-audited financials were approved and taken on record by the Board of Directors of the Company at their meeting held on Friday, 5th February 2016.

The Company proposes release of press note as per the enclosed format. This is for your information and records. Kindly acknowledge the receipt of the same.

Thanking You,

Yours faithfully,
For Divi's Laboratories Limited


P V Lakshmi Rajani
Company Secretary
(ACS 18882)



CIN : L24110TG1990PLC011854

“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off : Divi Towers, 7-1-77/E/1/303, Dharam Karan Road, Ameerpet, Hyderabad - 500 016. INDIA
Tel : 91-40-2378 6300, Fax : 91-40-2378 6460
E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS (STANDALONE)
FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2015

(Rs.in Lakhs)

	Particulars	STANDALONE					
		Quarter ended			Nine Months ended		Year Ended
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	Income from operations	85177	96187	78808	262055	225761	307230
	(a) Net Sales/Income from operations (Net of Excise Duty)						
	(b) Other Operating Income	110	245	304	540	931	1171
	Total Income from operations (net)	85287	96432	79112	262595	226692	308401
2	Expenses						
	a. Cost of materials consumed	33258	42106	34672	110931	105441	144627
	b. Purchases of stock-in-trade	0			0		0
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1512)	(3571)	(2808)	(8596)	(13626)	(23083)
	d. Employee benefits expense	9118	8595	7459	25746	20425	28315
	e. Depreciation and amortization expense	2988	3007	2879	8887	9131	13585
	f. Other Expenses	12194	11702	11080	34700	31546	42337
	Total Expenses	56046	61839	53282	171668	152917	205781
3	Profit from Operations before Other Income, Finance Costs & Exceptional Items (1-2)	29241	34593	25830	90927	73775	102620
4	Other Income	1520	2964	1994	7883	4817	4284
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	30761	37557	27824	98810	78592	106904
6	Finance Costs	23	34	48	79	127	186
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	30738	37523	27776	98731	78465	106718
8	Exceptional items	0	0	0	0	0	0
9	Profit from ordinary activities before Tax (7-8)	30738	37523	27776	98731	78465	106718
10	Tax Expense	6082	7950	5718	20184	16650	22012
11	Net Profit from ordinary activities after Tax (9-10)	24656	29573	22058	78547	61815	84706
12	Extra-ordinary items (net of tax expense)	0	0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	24656	29573	22058	78547	61815	84706
14	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	5309	5309	2655	5309	2655	2655



15	Reserves excluding revaluation reserves as per balance sheet of previous accounting year						353541
16	Earnings per Share (of Rs.2/- each) (not annualized):						
	a) Basic	9.29	11.14	8.31	29.59	23.29	31.91
	b) Diluted	9.29	11.14	8.31	29.59	23.29	31.91

NOTES:

- The above results for the quarter ended 31st December 2015, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 5th February, 2016 and were subjected to 'limited review' by the Auditors.
- The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
- The company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
- Details of forex gain/loss are given below:

Particulars	Quarter ended			Nine Months ended		Rs.in Lakhs
	31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	Year Ended
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Forex Gain/(Loss)	294	1166	1116	3582	1683	(105)

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

- Bonus Issue: The company has allotted 13,27,34,290 bonus shares of Rs.2 each to the members on 28th September, 2015. Earnings per Share has been adjusted for previous periods presented due to the bonus issue, in accordance with Accounting Standard No.20.
- Upon enactment of the Payment of Bonus (Amendment) Act, 2015, the company has made additional provision for bonus to employees, during the quarter, amounting to Rs.257 lakhs for the previous year 2014-15.
- Figures for the previous year/period have been regrouped or reclassified, wherever necessary.

Place: Visakhapatnam
Date: 05-02-2016



for Divi's Laboratories Limited

[Signature]

Dr. Murali K. Divi
Chairman & Managing Director



P.V.R.K. Nageswara Rao & Co.,
Chartered Accountants

INDEPENDENT AUDITOR'S REVIEW REPORT

TO
THE BOARD OF DIRECTORS OF
DIVI'S LABORATORIES LIMITED


We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **DIVI'S LABORATORIES LIMITED** ("the company") for the quarter and nine months ended **31st December, 2015** ("the Statement"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Accounting Standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.V.R.K. NAGESWARA RAO & Co.,
Chartered Accountants

Firm's Registration Number: 002283S


N. ANKA RAO

Partner

Membership Number: 23939



VISAKHAPATNAM
05.02.2016

DIVI'S LABORATORIES LIMITED
Hyderabad

PRESS RELEASE dated 5th February, 2016

Divi's Labs earns a PAT of Rs.247 crores in Q3/FY16

Divi's Laboratories has earned a Profit after Tax (PAT) of Rs.247 crores on a total income of Rs.853 crores, on a stand-alone basis, for the quarter ended 31st December, 2015. For the corresponding quarter of the last year the company earned a PAT of Rs.221 crores on a total income of Rs. 791 crores.

Forex gain for the current quarter amounted to Rs.3 crores as against a forex gain of Rs.11 crores during the corresponding quarter last year. The company has capitalized fixed assets aggregating to Rs.34 crores during the current quarter.

For the 9-month period ended 31st December, 2015, the company earned a total income of Rs.2626 crores as compared to Rs. 2267 crores during the corresponding 9-month period of last year. PBT for the current 9-month period came to Rs.987 crores as against a PBT of Rs. 785 crores for the previous period. PAT for the current 9-months is Rs.785 crores as against Rs. 618 crores for the previous period.

